Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer|
No Contacts or Locations Provided